SCR-A003 / Simcere - LARVOL DELTA

Preclinical development of SCR-A003, a novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting LIV-1 for solid cancer (AACR 2025) - "SCR-A003, exhibited a favorable preclinical profile, with potent in vivo activity toward LIV-1-expressing tumor xenografts representing a range of cancer indications. These data support clinical development of SCR-A003 for the treatment of LIV-1-expressing solid cancers."

Preclinical • Breast Cancer • Melanoma • Oncology • Ovarian Cancer • Solid Tumor • SLC39A6